1. An immature subset of neuroblastoma cells synthesizes retinoic acid and depends on this metabolite
- Author
-
Sofie Mohlin, Peter Stroeken, van Nes J, Franciska Haneveld, Alvin Chan, Niklasson Cu, Daniel Bexell, van Sluis P, Nurdan Akogul, Jan Koster, Rogier Versteeg, Linda J. Valentijn, Frank Westermann, Nancy E. Hasselt, Selina Jansky, Ellen M. Westerhout, van Groningen T, Arjan Lakeman, von Stedingk K, Sven Påhlman, Caroline Wigerup, Danny A. Zwijnenburg, Mohamed Hamdi, and Igor Adameyko
- Subjects
animal structures ,Mesenchymal stem cell ,Retinoic acid ,Adrenergic ,Motility ,Schwann cell ,Endogeny ,Biology ,medicine.disease ,In vitro ,chemistry.chemical_compound ,medicine.anatomical_structure ,chemistry ,Neuroblastoma ,Cancer research ,medicine - Abstract
Neuroblastoma is a pediatric tumor of the adrenergic sympathetic lineage. Most high risk neuroblastoma go in complete clinical remission by chemotherapy, which is subsequently complemented by retinoic acid (RA) maintenance therapy. However, by unresolved mechanisms most tumors ultimately relapse as therapy-resistant disease. Neuroblastoma cell lines were recently found to include, besides lineage committed adrenergic (ADRN) tumor cells, also immature mesenchymal (MES) tumor cells. Here, we report that MES-type cells synthesize RA and require this metabolite for proliferation and motility. MES cells are even resistant to RA in vitro. MES cells appear to resemble Schwann Cell Precursors (SCP), which are motile precursors of the adrenergic lineage. MES and SCP cells express shared RA-synthesis and RA-target genes. Endogenous RA synthesis and RA resistance thus stem from normal programs of lineage precursors that are maintained in an immature tumor cell fraction. These cells are fully malignant in orthotopic patient-derived xenograft models and may mediate development of drug-resistant relapses.
- Published
- 2021
- Full Text
- View/download PDF